CN117396501A - 抗sars-cov-2抗体及其用途 - Google Patents

抗sars-cov-2抗体及其用途 Download PDF

Info

Publication number
CN117396501A
CN117396501A CN202180085791.0A CN202180085791A CN117396501A CN 117396501 A CN117396501 A CN 117396501A CN 202180085791 A CN202180085791 A CN 202180085791A CN 117396501 A CN117396501 A CN 117396501A
Authority
CN
China
Prior art keywords
yang
antibody
impi
domain
domain sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180085791.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·凯拉姆
A·帕尔瑟
V·格尔马谢夫斯基
S·J·沃森
B·D·格里姆肖
S·宾特
J·M·萨里
M·比洛
R·罗兰兹
A·克里希纳
林焕钧
杨政远
刘丽莺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemab Co ltd
Original Assignee
Kemab Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemab Co ltd filed Critical Kemab Co ltd
Publication of CN117396501A publication Critical patent/CN117396501A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
CN202180085791.0A 2020-10-27 2021-10-27 抗sars-cov-2抗体及其用途 Pending CN117396501A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2017058.5 2020-10-27
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof
PCT/EP2021/079901 WO2022090353A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof

Publications (1)

Publication Number Publication Date
CN117396501A true CN117396501A (zh) 2024-01-12

Family

ID=73727037

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180085791.0A Pending CN117396501A (zh) 2020-10-27 2021-10-27 抗sars-cov-2抗体及其用途

Country Status (12)

Country Link
US (1) US20250026813A1 (enExample)
EP (1) EP4237442A1 (enExample)
JP (1) JP2023549067A (enExample)
KR (1) KR20230113295A (enExample)
CN (1) CN117396501A (enExample)
AU (1) AU2021369450A1 (enExample)
CA (1) CA3199594A1 (enExample)
CO (1) CO2023006684A2 (enExample)
GB (1) GB202017058D0 (enExample)
IL (1) IL302244A (enExample)
MX (1) MX2023004869A (enExample)
WO (1) WO2022090353A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
CN114989263B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用
CN114989255B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN121002058A (zh) * 2022-12-09 2025-11-21 艾布维兹生物公司 针对SARS-CoV-2及其变体的抗体或其片段
CN120981481A (zh) * 2023-01-10 2025-11-18 萨那生物技术股份有限公司 Cd19特异性抗体构建体以及它们的组合物
KR20250016745A (ko) * 2023-07-25 2025-02-04 연세대학교 산학협력단 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof

Also Published As

Publication number Publication date
AU2021369450A9 (en) 2025-04-10
WO2022090353A1 (en) 2022-05-05
US20250026813A1 (en) 2025-01-23
EP4237442A1 (en) 2023-09-06
AU2021369450A1 (en) 2023-06-22
GB202017058D0 (en) 2020-12-09
JP2023549067A (ja) 2023-11-22
MX2023004869A (es) 2023-06-01
CO2023006684A2 (es) 2023-05-29
KR20230113295A (ko) 2023-07-28
IL302244A (en) 2023-06-01
CA3199594A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
US20250026813A1 (en) Antibodies against sars-cov-2 and uses thereof
US12435134B2 (en) Antagonists anti-CD7 antibodies
ES2973425T3 (es) Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
JP6535675B2 (ja) 抗ａ型インフルエンザ抗体の中和及びその使用
TWI613214B (zh) 抗血球凝集素抗體及使用方法
Ko et al. A non-neutralizing antibody broadly protects against influenza virus infection by engaging effector cells
AU2021203744A1 (en) Treatment regimens using anti-NKG2A antibodies
US10273288B2 (en) Neutralizing antibodies to Ebola virus glycoprotein and their use
JP2023078352A (ja) 中和抗インフルエンザ結合分子及びその使用
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
CN118829653A (zh) 用tl1a抑制剂和il23抑制剂的组合治疗炎性疾病的方法
JP2023528072A (ja) ＳＡＲＳ－ＣｏＶ－２糖タンパク質Ｓに対する中和活性を有する治療用抗体
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
US20230357364A1 (en) Covid-19 antibodies and uses thereof
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
WO2024030829A1 (en) Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
JP2024533166A (ja) 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
JP2024504167A (ja) Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
RU2832110C1 (ru) Поливалентная векторная вакцина hvt
CA3102329C (en) Novel anti-cd39 antibodies
WO2025184137A1 (en) Influenza antibodies and methods of use thereof
WO2022162097A2 (en) Antibodies and uses thereof
CN119213024A (zh) hMPV抗体及其用途
CN116916958A (zh) 用于sars-cov-2感染的抗体疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination